Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4.

Hansen DK, Lu X, Puglianini OC, Sorensen S, Usmani SZ, Zhang E, Huo S, Zhang Y, Qureshi ZP, Jagannath S.

Open source

DOI: 10.3389/fimmu.2024.1408892
Published: 2024-08-21
Container: Front Immunol
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2024.1408892,
  title = {Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4.},
  author = {Hansen DK and  Lu X and  Puglianini OC and  Sorensen S and  Usmani SZ and  Zhang E and  Huo S and  Zhang Y and  Qureshi ZP and  Jagannath S.},
  year = {2024},
  journal = {Front Immunol},
  doi = {10.3389/fimmu.2024.1408892},
  url = {https://doi.org/10.3389/fimmu.2024.1408892}
}

RIS

TY  - JOUR
TI  - Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4.
AU  - Hansen DK
AU  -  Lu X
AU  -  Puglianini OC
AU  -  Sorensen S
AU  -  Usmani SZ
AU  -  Zhang E
AU  -  Huo S
AU  -  Zhang Y
AU  -  Qureshi ZP
AU  -  Jagannath S.
PY  - 2024
JO  - Front Immunol
DO  - 10.3389/fimmu.2024.1408892
UR  - https://doi.org/10.3389/fimmu.2024.1408892
ER  -

APA

DK, H., X, L., OC, P., S, S., SZ, U., E, Z., S, H., Y, Z., ZP, Q., & S., J. (2024). Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4.. Front Immunol. https://doi.org/10.3389/fimmu.2024.1408892

Source records

europe-pmc · retrieved 2026-09-27T07:00:29.619Z
doaj · retrieved 2026-09-27T07:00:29.636Z